This pattern is consistent in many cancers where targeting GH action has shown therapeutic promise, including melanoma [20,21,22,24,33], pancreatic cancer [23,34,94], breast cancer [13,15,19,26,35,95,96,97,98], and prostate cancer [99,100,101,102,103,104], among others. This evidence concerns the gene GH1 and prostate carcinoma.